1. A highly-safe live auxotrophic vaccine protecting against disease caused by non-typhoidal Salmonella Typhimurium in mice
- Author
-
Patricia García, Miriam Moscoso, Víctor Fuentes-Valverde, M. Rosario Rodicio, Silvia Herrera-León, Germán Bou, Xunta de Galicia (España), Centro de Investigación Biomédica en Red - CIBERINFEC (Enfermedades Infecciosas), Instituto de Salud Carlos III, Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF), and Red de Investigación Cooperativa en Investigación en Patología Infecciosa (España)
- Subjects
Microbiology (medical) ,Infectious Diseases ,General Immunology and Microbiology ,Immunology and Allergy ,Non-typhoidal Typhimurium ,Non-typhoidal Salmonella Typhimurium ,Live auxotrophic vaccines ,General Medicine ,D-glutamate ,Intestinal infection model ,Mucosal vaccine ,D-alanine ,Non-typhoidal Salmonella - Abstract
Background: Salmonella enterica serovar Typhimurium (S. Typhimurium) has become an important intestinal pathogen worldwide and is responsible for lethal invasive in fections in populations at risk. There is at present an unmet need for preventive vaccines. Methods: IRTA GN-3728 genome was sequenced by Illumina and D-glutamate and D-glutamate/D-alanine knockout-auxotrophs were constructed. They were characterized using electron mi croscopy, growth/viability curves, reversion analysis, and motility/agglutination assays. Their potential as vaccine candidates were explored using two BALB/c mouse models for Salmonella infections: a systemic and an intestinal inflammation. Clinical signs/body weight and survival were monitored, mucosal lactoferrin and specific/cross-reactive IgA/IgG were quantified by enzyme-linked-immunosorbent assays and bacterial shedding/burden in fecal/tissues were evaluated. Results: The D-glutamate auxotroph, IRTA DmurI, is highly attenuated, immunogenic and fully protective against systemic infection. The IRTA DmurI Dalr DdadX double auxotroph, con structed to reinforce vaccine safety, showed a higher level of attenuation and was 100% effec tive against systemic disease. In the intestinal model, it proved to be safe, yielding a low degree of mucosal inflammation, short-term shedding and undetectable invasiveness in the long-term, while eliciting cross-reactive fecal IgA/serum IgG against clinically relevant multidrug-resistant (MDR) S. Typhimurium strains. It also conferred protection against homol ogous oral challenge, and protected mice from local and extra-intestinal dissemination caused by one MDR strain responsible for an international outbreak of highly severe human infections. Additionally, oral vaccination promoted extended survival after lethal heterologous infection. Conclusion: This study yielded a very safe S. Typhimurium vaccine candidate that could be further refined for mucosal application against disease in humans. This study was supported by a grant from SERGAS (The Galician Healthcare Service) (Programs “InnovaSaude” and “InnovaMicrolab”), the Spanish Network for Research in Infectious Diseases (RD16/0016/0006), CIBERINFEC, project PI18/00501, funded by Instituto de Salud Carlos III and co funded by European Union (ERDF, “A way to make Europe”), and PI21/00704, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, awarded to GB, and by CZ Vaccines. VFV is funded by a predoctoral fellowship from Xunta de Galicia (IN606A-2019/012). Sí
- Published
- 2023